• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经母细胞瘤中的自然杀伤细胞:免疫见解和治疗观点。

Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives.

机构信息

St. Anna Children's Cancer Research Institute, Vienna, Austria.

Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Cancer Metastasis Rev. 2024 Dec;43(4):1401-1417. doi: 10.1007/s10555-024-10212-8. Epub 2024 Sep 18.

DOI:10.1007/s10555-024-10212-8
PMID:39294470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11554946/
Abstract

Natural killer (NK) cells have multifaceted roles within the complex tumor milieu. They are pivotal components of innate immunity and shape the dynamic landscape of tumor-immune cell interactions, and thus can be leveraged for use in therapeutic interventions. NK-based immunotherapies have had remarkable success in hematological malignancies, but these therapies are met with many challenges in solid tumors, including neuroblastoma (NB), a childhood tumor arising from the sympathetic nervous system. With a focus on NB, this review outlines the mechanisms employed by NK cells to recognize and eliminate malignant cells, delving into the dynamic relationship between ligand-receptor interactions, cytokines, and other molecules that facilitate the cross talk between NK and NB cells. We discuss the immunomodulatory functions of NK cells and the mechanisms that contribute to loss of this immunosurveillance in NB, with a focus on how this dynamic has been utilized in recent immunotherapy advancements for NB.

摘要

自然杀伤 (NK) 细胞在复杂的肿瘤微环境中具有多方面的作用。它们是先天免疫的关键组成部分,塑造了肿瘤-免疫细胞相互作用的动态景观,因此可被用于治疗干预。基于 NK 细胞的免疫疗法在血液恶性肿瘤中取得了显著成功,但这些疗法在实体瘤中面临许多挑战,包括神经母细胞瘤 (NB),这是一种起源于交感神经系统的儿童肿瘤。本文重点关注 NB,概述了 NK 细胞识别和消除恶性细胞所采用的机制,深入探讨配体-受体相互作用、细胞因子和其他分子之间的动态关系,这些关系促进了 NK 和 NB 细胞之间的串扰。我们讨论了 NK 细胞的免疫调节功能以及导致 NB 中这种免疫监视丧失的机制,重点介绍了这种动态如何在最近用于 NB 的免疫治疗进展中得到利用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76cd/11554946/38f72f70ae8b/10555_2024_10212_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76cd/11554946/e3fe714e8f2c/10555_2024_10212_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76cd/11554946/38f72f70ae8b/10555_2024_10212_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76cd/11554946/e3fe714e8f2c/10555_2024_10212_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76cd/11554946/38f72f70ae8b/10555_2024_10212_Fig2_HTML.jpg

相似文献

1
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives.神经母细胞瘤中的自然杀伤细胞:免疫见解和治疗观点。
Cancer Metastasis Rev. 2024 Dec;43(4):1401-1417. doi: 10.1007/s10555-024-10212-8. Epub 2024 Sep 18.
2
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.GD2 导向的 CAR T 与激活的 NK 细胞介导的 IFNγ 分泌克服了 MYCN 依赖性 IDO1 抑制,有助于神经母细胞瘤细胞的免疫逃逸。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001502.
3
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.双唾液酸神经节苷脂特异性人类自然杀伤细胞对耐药性神经母细胞瘤有效。
Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.
4
Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.激活的浆细胞样树突状细胞刺激患者的 NK 细胞可增强依维莫司诱导的神经母细胞瘤杀伤作用。
Cancer Immunol Immunother. 2020 Sep;69(9):1767-1779. doi: 10.1007/s00262-020-02581-0. Epub 2020 Apr 27.
5
Identification of neuroblastoma cell lines with uncommon TAZ/mesenchymal stromal cell phenotype with strong suppressive activity on natural killer cells.鉴定具有罕见 TAZ/间充质基质细胞表型的神经母细胞瘤细胞系,其对自然杀伤细胞具有强烈的抑制活性。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001313.
6
Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.神经母细胞瘤向间充质状态的转变可能表现为 GD2 高表达,并获得对 NK 细胞的免疫逃逸。
Front Immunol. 2024 Apr 26;15:1382931. doi: 10.3389/fimmu.2024.1382931. eCollection 2024.
7
The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.白细胞介素-2、全反式维甲酸和自然杀伤细胞在神经母细胞瘤抗 GD2 抗体治疗中的作用:监测机制。
Cancer Immunol Immunother. 2018 Apr;67(4):615-626. doi: 10.1007/s00262-017-2108-6. Epub 2018 Jan 11.
8
Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.通过激活 iNKT 和 NK 细胞增强神经母细胞瘤免疫疗法。
Front Immunol. 2020 May 8;11:873. doi: 10.3389/fimmu.2020.00873. eCollection 2020.
9
NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.来自先前接触过神经母细胞瘤细胞的自然杀伤细胞的外泌体增强细胞因子激活的自然杀伤细胞的抗肿瘤活性。
J Immunother. 2017 Sep;40(7):265-276. doi: 10.1097/CJI.0000000000000179.
10
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.表达 PD-L1 的自然杀伤细胞预测神经母细胞瘤的预后良好,并对 PD-1/PD-L1 阻断有反应。
Oncoimmunology. 2023 Dec 1;13(1):2289738. doi: 10.1080/2162402X.2023.2289738. eCollection 2024.

引用本文的文献

1
Biphasic behavior of T cell subsets reflects failure of early anti-myeloma response and leads to progressive T cell dysfunction.T细胞亚群的双相行为反映了早期抗骨髓瘤反应的失败,并导致进行性T细胞功能障碍。
Neoplasia. 2025 Sep;67:101208. doi: 10.1016/j.neo.2025.101208. Epub 2025 Jul 11.
2
Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma.神经母细胞瘤中表观基因组、微环境与免疫系统之间的相互作用
Cancers (Basel). 2025 May 29;17(11):1812. doi: 10.3390/cancers17111812.
3
Peptidergic Systems and Neuroblastoma.

本文引用的文献

1
High-dimensional single-cell analysis of human natural killer cell heterogeneity.人类自然杀伤细胞异质性的高维单细胞分析
Nat Immunol. 2024 Aug;25(8):1474-1488. doi: 10.1038/s41590-024-01883-0. Epub 2024 Jul 2.
2
Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases.多特异性免疫细胞衔接器在癌症和传染病中的应用。
Cell Mol Immunol. 2024 Jul;21(7):643-661. doi: 10.1038/s41423-024-01176-4. Epub 2024 May 24.
3
TGF-β signaling in health, disease, and therapeutics.TGF-β 信号在健康、疾病和治疗中的作用。
肽能系统与神经母细胞瘤
Int J Mol Sci. 2025 Apr 8;26(8):3464. doi: 10.3390/ijms26083464.
4
Association of Neuroblastoma (NB) SH-SY5Y Cells with Antibodies of Parasitic Origin (Anti- and Anti-).神经母细胞瘤(NB)SH-SY5Y细胞与寄生虫源抗体(抗……和抗……)的关联
Int J Mol Sci. 2024 Dec 19;25(24):13577. doi: 10.3390/ijms252413577.
Signal Transduct Target Ther. 2024 Mar 22;9(1):61. doi: 10.1038/s41392-024-01764-w.
4
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?贝伐珠单抗联合化疗治疗复发性/进展性高危神经母细胞瘤患儿的疗效分析:化疗方案是否重要?
Eur J Cancer. 2024 May;202:114001. doi: 10.1016/j.ejca.2024.114001. Epub 2024 Mar 11.
5
Development of NK cell-based cancer immunotherapies through receptor engineering.通过受体工程开发基于自然杀伤细胞的癌症免疫疗法。
Cell Mol Immunol. 2024 Apr;21(4):315-331. doi: 10.1038/s41423-024-01145-x. Epub 2024 Mar 5.
6
Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.通过抑制犬尿氨酸-AHR 通路靶向神经母细胞瘤细胞。
FEBS J. 2024 May;291(10):2172-2190. doi: 10.1111/febs.17109. Epub 2024 Mar 3.
7
Breakthrough of solid tumor treatment: CAR-NK immunotherapy.实体瘤治疗的突破:CAR-NK免疫疗法。
Cell Death Discov. 2024 Jan 20;10(1):40. doi: 10.1038/s41420-024-01815-9.
8
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.单细胞 RNA 测序对神经母细胞瘤的综合分析确定 NECTIN2-TIGIT 轴为免疫治疗的靶点。
Cancer Cell. 2024 Feb 12;42(2):283-300.e8. doi: 10.1016/j.ccell.2023.12.008. Epub 2024 Jan 4.
9
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.对于高危神经母细胞瘤,采用GM-CSF、G-CSF或不进行细胞因子治疗联合抗GD2免疫疗法。
Int J Cancer. 2024 Apr 15;154(8):1340-1364. doi: 10.1002/ijc.34815. Epub 2023 Dec 18.
10
Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.增强自然杀伤细胞的功能以克服癌症对基于 NK 细胞治疗的耐药性,并增强基于抗体的免疫疗法。
Front Immunol. 2023 Nov 24;14:1275904. doi: 10.3389/fimmu.2023.1275904. eCollection 2023.